Shandong Weigao Group repurchases shares, increasing treasury holdings

Shandong Weigao Group Medical Polymer Company Limited announced a share repurchase on November 17, 2025. The company repurchased 243,600 ordinary H shares on the Exchange at a volume-weighted average price. The repurchase price per share ranged from HK$5.36 to HK$5.42, costing HK$1,313,532.

This event led to a decrease in issued shares (excluding treasury shares) by 243,600, representing 0.0054% of the existing number of issued shares before the event. Consequently, the number of treasury shares increased from 24,870,000 to 25,113,600. The total number of issued shares remains 4,522,332,324.

The repurchase was made under a mandate granted on May 27, 2025, which authorized the repurchase of up to 451,560,392 shares. With this latest transaction, the total number of shares repurchased under the current mandate stands at 18,465,200. This represents 4.0892% of the issued shares as of the mandate's grant date. The company is under a moratorium period for any new share issue or treasury share sale until December 16, 2025.